Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 March 1999

Results of palliative cytoreduction chemotherapy in patients with advanced non-small cell lung cancer

Anna Słowik-Gabryelska, Agata Kalicka, Władysław Lasek

Med Sci Monit 1999; 5(2): CR226-232 :: ID: 505091

Abstract

Large number of patients with advanced non-small cell lung cancer (NSCLC), poor prognosis and controversies on the effectiveness of chemotherapy in advanced cases made us analyse our experiences in that matter. The results of paliative chemotherapy in 110 inoperable, and disqualified from radiotherapy NSCLC patients (stage III B, IV) received 2-6 courses of chemotherapy by Le Chevalier (Vincristin, Cyclophosphamide, Lomustine, Cisplatin) or by Rosell (Mitimycin, Ifosfamide, Cisplatin). Control group consisted of 20 persons with advanced NSCLC, who received paliative radiotherapy. The effectiveness of therapy was established on the basis of survival time, number and quality of remissions and performance status. It was established, that effectiveness of treatment depended upon the tolerance of chemotherapy. The more courses of chemotherapy the more remissions, and longer time of survival. The mean time of survival in symptomatically treated patients was 3 months, whereas in chemotherapy group - 11.8 months. In chemotherapy group, the remissions in 82% of patients were obtained, among them 22% complete tumour regressions. Mean time of survival was: 16.1 months in CR, 11.2 months in PR and 5.1 month in patients without answer to treatment. The obtained remissions allowed to resect the tumour in 12% of patients and to apply radiotherapy in about 50%;. In significant part of patients, after chemotherapy the improvement of performance status was seen. The obtained results of treatment are comparable with others in Europe and the USA.

Keywords: palliative chemotherapy, therapy, lung cancer

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750